Lidoderm

Drug: Lidoderm
Generic: Lidocaine patch 5%
The company: Endo Health Solutions/ EpiCept
Patent expiration date: Sept. 15, 2013
Estimated Global Sales 2012: $918 million

The scoop: Endo Health Solutions ($ENDP) faces a grim outlook next September when the company's biggest revenue driver, the pain-relieving patch Lidoderm, falls off patent. Lidoderm brought in $228 million, or 29% of Endo's total sales, in the second quarter. And Watson Pharmaceutical ($WPI) has its finger on the trigger with a lidocaine topical patch 5% it plans to launch when that patent expires In May, Endo settled a lawsuit with the company allowing it to launch a generic version of Lidoderm, and pay one-fourth of gross profits as royalties to Endo. That came at no small cost to Endo; the company endured an 83% drop in second-quarter profits related to patent litigation with Watson. Lidoderm earned $918 million in estimated sales this year; the company forecasts earnings below market expectations in 2013.

For more:
Endo seeks protections in House FDA reauthorization

Lidoderm
Read more on

Suggested Articles

AbbVie and Roche are looking to move Venclexta deeper into the blood cancer arena, but their multiple myeloma ambitions just took a hit.

Starboard Value's 197-page presentation against the BMS-Celgene deal lacks a "smoking gun," an analyst wrote. He believes the deal will go…

Bayer's sale of its animal health unit is attracting interest from a wide variety of players, including private equity firms and even rivals, a new report…